Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUPHORIA Study
2024-519337-35-00Phase 4Authorised
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of eptinezumab in migraine (2 arms), sponsored by IRCCS Ospedale San Raffaele. Planned start Apr 2025; status: authorised.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on 2024-519337-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519337-35-00.